1. Comely O.A., Ullmann A.J., Karthaus M. (2003): Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood, 101, 3365–3372.
2. Kohno S., Yamaguchi H. (2002): Overview of micafungin (MCFG). Jap. J. Chemother., 50(S−1), 1–7.
3. Ikeda F., Otomo K., Nakai T., Morishita Y., Maki K., Tawara S., Mutoh, S., Matsumoto. F., Kuwahara, S. (2002): In vitro activity of a new lipopeptide antifungal agent, micafungin against a variety of clinically important fungi. Jap. J. Chemother., 50(S−1), 8–19.
4. van Burik J.A., Ratanatharathorn V., Stepan D.E., Miller C.B., Lipton J.H., Vesole D.H., Bunin N., Wall D.A., Hiemenz J.W., Satoi Y., Lee J.M., Walsh T.J.; National Institute of Allergy and infectious Diseases Mycoses Study Group. (2004): Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis., 39, 1407–1416.
5. Ishikawa T., Takata T., Tomoyose T., Masuda M., Nakachi S., Koga S., Tsukada J., Matsuura A., Utsunomiya A., Saburi Y., Tamura K. (2006): The efficacy of micafungin as an empiric therapy for febrile neutropenic patients refractory to antibacterial agents. Jap. J. Chemother., 54, 125–128.